Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from ZyVersa Therapeutics ( (ZVSA) ) is now available.
On July 15, 2025, ZyVersa Therapeutics, Inc. received a determination letter from Nasdaq indicating that the Nasdaq Hearings Panel has denied the company’s request to continue its listing on The Nasdaq Capital Market. Due to non-compliance with the minimum bid price requirements, the company’s securities are set to be delisted, with trading suspended on July 17, 2025. In response, ZyVersa plans to apply for trading on the Pink Limited Market to mitigate the impact of delisting, with trading expected to begin on or about July 17, 2025, under the symbol ‘ZVSA.’ This move may result in a limited market for the company’s shares, potentially affecting stockholder liquidity and trading prices.
The most recent analyst rating on (ZVSA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on ZyVersa Therapeutics stock, see the ZVSA Stock Forecast page.
Spark’s Take on ZVSA Stock
According to Spark, TipRanks’ AI Analyst, ZVSA is a Underperform.
ZyVersa Therapeutics faces significant financial challenges with no revenue and ongoing losses. Technical indicators show bearish momentum, and the negative P/E ratio suggests overvaluation concerns. The lack of dividend yield further limits investment appeal.
To see Spark’s full report on ZVSA stock, click here.
More about ZyVersa Therapeutics
Average Trading Volume: 5,594,999
Technical Sentiment Signal: Sell
Current Market Cap: $2.77M
Learn more about ZVSA stock on TipRanks’ Stock Analysis page.